The University of Miami Leonard M. Miller School of Medicine and Boston-based biopharmaceutical company, Berg have entered into an agreement for collaborative research and for sharing research data and both are giving the boot-critical projects on cancer, metabolic disorders and diseases of the central nervous system.  

Berg, also founded by the student Niven R Narain 's Miller School of Medicine has funded more than $ 10 million US in grants for research over the past 10 years. Formalized this partnership is expected to increase even more its value and accelerate the placement of Miami as an emerging hub for biotechnology.

Access to award-winning discovery platform Interrogative Biology  Berg will be crucial for the University of Miami , which previously has already produced assets and enablers for therapeutic clinical stage IND for cancer and metabolic disorders, in addition to the assets and diagnostic markers of prostate cancer and cardiac collapse. In turn, Berg will have access to human resources of high-level researchers and clinical investigators, as well as tissue samples with clinical annotations in addition to blood samples, urine and other samples which Miller School of Medicine is rich, considered in particular, the diversity of the population of Florida South.

"The future of health care will be carried out on an interface and a deeper understanding of how biology and technology can work together. Berg has a wide range of targets and markers of disease, and ready to be validated for clinical use, " said co-founder, chairman, and chief technical officer Niven R Narain. "Together with top researchers of the University of Miami and the diversity of tissue samples, we can help to catalyze the discovery of some of our most difficult and debilitating diseases. "

In addition, Berg will have the opportunity to fund initial projects and provide support to critical research and development to the thought leaders of the Miller School of Medicine in the basic sciences, in research and clinical trials to stimulate transactional relationships without barriers and only between industry and academia. In concert, the School of Medicine will provide the Berg its experience and its resources, and will also fund initial projects that will make use of the technologies of Berg to spur innovation from the benchmark to the hospital ward.

"We live in a time when the intersection between biology and technology is bringing to light new insights into the mechanisms of the diseases that in the past would not have been imaginable," said Pascal J Goldschmidt, vice president of medical affairs and Dean of Senio the Miller School and CEO of UHealth. "Through this collaboration, the University of Miami and Berg are found to occupy a unique position to improve the traditional industry-academia relationship, by removing barriers to free resources for the benefit of both parties and bring significant breakthroughs in order to obtain results best for patients. "

For example, the University of Miami and Berg together will leverage their combined clinical experience and research skills to access a`nd critical markets such as cancer, diabetes and cardiovascular disease. Under the guidance of Goldschmidt , recognized as one of the world's most famous cardiologists, Berg will establish a partnership with the University of Miami for a new marker for cardiac collapse. In addition, the innovative work will be done in the field of diabetes to identify new methods of administration of medicines for diabetes sufferers, that have the potential to eliminate the need to depend on insulin for the diabetic population.
]
"By working with our faculty for entrepreneurship and with our partners in the Office Administration Research, Innovation U team is fully dedicated to creating and supporting new partnerships that will accelerate the development of promising discoveries. We look forward to working with Berg Pharma team, "added Norma Kenyon, Head of Head of Innovation at the Miller School of Medicine and vice chancellor for innovation of the University of Miami.

"In biomedical research it is important to take discoveries from the lab to patients in the shortest possible time. Collaboration of academic researchers with industry scientists, as will happen with Berg, expedites entry into the market. This collaboration will also help the formation of our students for research-oriented careers, "said Professor Sylvia Daunert, Ph.D., Pharm.D., MS and Lucille P. Markey Chair of the Department of Biochemistry and Molecular Biology, and Associate Director of the Dr. John T . Macdonald Foundation Biomedical Nanotechnology Institute.

According to Narain , the relationship between Berg and the University of Miami marks an important milestone in the development of Florida as a suitable environment for biotechnology. It also considers that this agreement is a promising bridge between Miami and hub for research with a long tradition, such as Boston , which can operate from exchange valuable for innovation in the field of health and clinical.

"The best cities in the world are defined by their ability to innovate and educate educated, and this partnership further demonstrates the pivotal role that the Miller School of Medicine of the University of Miami is playing in supporting the biotech boom of Florida , "said Nancy K. Bryan , President and CEO of BioFlorida. "We can expect that other investments are made ??in the areas of medical research and drug discovery, while companies such as Berg continue to expand their relations in the region."

Berg, the namesake of Carl Berg , is a biopharmaceutical company and parent company of Parma Berg , Berg and Berg Diagnostics Biosistema.

The Leonard M. Miller School of Medicine of the University of Miami was founded in 1952 and is the first medical school in Florida. It is known nationally and internationally for innovation in research, patient care, medical education and community service in the United States, Latin America and the Caribbean.